Spartalizumab Safety for Cancer

Recruiting in Palo Alto (17 mi)

+53 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Novartis Pharmaceuticals

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial aims to ensure that spartalizumab remains safe and tolerable for patients who are already using it. The medication helps the immune system fight cancer, and the study ensures patients can keep accessing it safely.

Eligibility Criteria

This trial is for patients already participating in a Novartis-sponsored study, receiving spartalizumab alone or with other treatments for solid tumors. They must be benefiting from the treatment as judged by their doctor and meet all other ongoing study requirements.

Inclusion Criteria

I am currently in a Novartis study and receiving spartalizumab.

I am benefiting from the current treatment, as confirmed by my doctor.

I am currently in a Novartis study and receiving spartalizumab alone or with other treatments.

+1 more

Exclusion Criteria

I was taken off spartalizumab for reasons other than joining another study.

Subject does not meet the criteria specified in the parent protocol criteria for continued study treatment.

Participant Groups

The trial continues to evaluate the safety and tolerability of spartalizumab, an investigational drug, given either alone or alongside other treatments to those who have been taking it and are seeing positive results.

1Treatment groups

Experimental Treatment

Group I: PDR001Experimental Treatment1 Intervention

All subjects in all combination will be entered in one arm